Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on August 8, 2014. The filing serves to announce the company's financial results for the three and six months ended June 30, 2014, alongside an update on its business and clinical programs. The detailed results are contained in a press release attached as Exhibit 99.01.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.01) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms that a press release detailing these results and program updates was issued on the date of the report.
Guidance, Outlook, and Risks
The company provided a business and clinical programs update in the referenced press release. The filing explicitly states that the information furnished under Item 2.02 and the accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of such section, nor is it incorporated by reference in subsequent filings except as specifically stated.
Investor Verification Checklist
- Review Exhibit 99.01 (Press Release Dated August 8, 2014) for specific financial figures and clinical trial updates.
- Verify the company name discrepancy: The request metadata lists "PALISADE BIO, INC.", but the filing is for "Neuralstem, Inc."
- Confirm the status of clinical programs mentioned in the attached press release.
- Note the legal disclaimer regarding the non-filing status of the financial data within this specific 8-K document.